Skip to main content

Table 2 Descriptive analysis of full economic evaluations for hepatocellular carcinoma

From: Economic evaluations of radioembolization with Itrium-90 microspheres in hepatocellular carcinoma: a systematic review

Author, year, publication type and country

Patient’s characteristics

Treatments

Analysis type/model

Perspective/time horizon

Cost

Outcomes

Comparators

Microspheres

TARE versus TACE

       

Rostambeigi, 2014 [20]

Original article

USA

BCLC-A

BCLC-B

BCLC-C

TARE versus TACE

TheraSphere™

SIR-Spheres®

CEA/Monte Carlo

Payer/5 years

Direct cost (medical)

OS and incremental cost

Rostambeigi, 2014 [21]

Communication at congress

USA

BCLC-A

BCLC-B

BCLC-C

TARE versus TACE

ND

CEA/Monte Carlo

Payer/5 years

ND

OS, procedure- and complications costs, and incremental cost

Manas, 2021 [22]

Original article

United Kingdom

BCLC-A

BCLC-B

TARE versus TACE, TAE o DEB-TACE

TheraSphere™

CUA/Markov

Payer/20 years

Direct cost (medical)

Downstaginga, LYG, QALY, ICER(£/LYG) y ICUR(£/QALY)

Rognoni, 2018 [23]

Original article

Italy

BCLC-B

TTS: TARE + TACE + sorafenib (on 47% of patients)

TS: TARE + sorafenib

TheraSphere

SIR-Spheres®

CUA/Markov

Payer/lifetime

Direct cost (medical)

Cost, QALY, ICUR (€/QALY), WTP a €50,000/QALY

TARE versus TKIs

       

Chaplin, 2015 [24]

Communication at congress

United Kingdom

BCLC-Cb

TARE versus sorafenib

TheraSphere

CUA/Markov

Payer/10 years

ND

Cost, TTP, SG y ICUR (£/QALY),

Palmer, 2017 [25]

Communication at congress

United Kingdom

BCLC-C

TARE versus sorafenib

SIR-Spheres®

Cost-minimization analysis

Payer/ND

Direct cost (medical)

Cost (£), principals factors cost, QALY

Rognoni, 2017 [26]

Original article

Italy

BCLC-B

BCLC-C

TARE versus sorafenib

ND

CUA/Markov

Payer/lifetime

Direct cost (medical)

Cost, QALY, ICUR (€/QALY), WTP a €38,500 (~ £30,000)/QALY

Parikh, 2018 [27]

Communication at congress

USA

BCLC-Cc

TARE versus sorafenib

ND

CUA/Markov

Payer/lifetime

Direct cost (medical)

ICUR ($/QALY)

Walton, 2020 [28]

Systematic review an economic evaluation

United Kingdom

BCLC-B

BCLC-C (Child–Pugh A e ineligible a CTT)

TARE versus TKIs

TheraSphere

SIR-Spheres®

QuiremSpheres®

CUA/Partitioned survival model and decision tree

Payer and social/10 years

Direct and indirect cost

ICUR (£/QALY), incremental net monetary (NMB)

Muszbek, 2020–21 [29]

Original article

United Kingdom

BCLC-Bd

BCLC-Cd

TARE versus sorafenib

SIR-Spheres®

CUA/Partitioned survival model

Payer/lifetime

Direct cost (medical)

Cost, LYG, QALY, ICUR (£/QALY), WTP a £20.000, INB

Marqueen, 2021 [30]

Original article

USA

BCLC-C

TARE versus sorafenib

TheraSphere

SIR-Spheres®

CUA/Markov

Payer/5 years

Direct cost (medical)

Cost, QALY, ICUR (€/QALY), WTP a $100,000/QALY o $200,000/QALY

  1. BCLC Barcelona Clinic Liver Cancer classification, CEA cost-effectiveness analysis, CTT conventional transarterial therapy, CUA cost-utility analysis, DEB-TACE doxorubicin eluting bead transarterial chemoembolization, HCC hepatocellular carcinoma, ICER cost-effectiveness incremental ratio, ICUR incremental cost-utility ratio, LYG LYG life-years gained, ND no data, OS overall survival, QALY quality-adjusted life years, TACE transarterial chemoembolization, TAE transarterial embolization, TARE transarterial radioembolization, TKI tyrosine kinase inhibitors, TTP time to progression, TTS sequency TARE, TACE and optional sorafenib (sorafenib was administered on 47% of patients), WTP willingness-to-pay
  2. aDownstaging: decrease in tumour burden that allows patients to be rescued for treatments such as liver transplantation
  3. bAssumed clinical characteristics of two separate RCTs: TheraSphere (Salem et al. 2011) and sorafenib (Phase III SHARP RCT-Llovet et al. 2018)
  4. cPatients with unresectable HCC and Child–Pugh class A cirrhosis
  5. dBCLC-B o BCLC-C (not appropriate to TACE): HCC with low tumour burden (≤ 25%) and good liver function (albumin–bilirubin [ALBI] grade 1)